GlucoTrack, Inc. filings document the regulatory, financial, and capital-structure disclosures of a medical technology company developing an implantable continuous blood glucose monitoring system for diabetes. Form 8-K reports cover Regulation FD releases on CBGM development, IDE-related disclosures, peer-reviewed study announcements, financial results, and corporate highlights.
The company’s filings also record material definitive agreements involving promissory-note exchanges for common stock, private-placement and exemption disclosures, beneficial-ownership limits, and shareholder voting matters. Proxy materials describe Nasdaq stock-issuance approvals, warrant-related share issuance proposals, meeting mechanics, governance procedures, and capital-structure matters tied to GlucoTrack’s public-company financing activities.
Glucotrack, Inc. (GCTK) is reported to have its common stock beneficially owned by White Lion Capital LLC, which reports beneficial ownership of 79,734 shares, representing 9.99% of the common stock outstanding, calculated under Rule 13d-3 as if certain ownership limits were 9.99%. White Lion directly owns 77,492 shares and may acquire additional shares under a stock purchase agreement, a senior convertible promissory note, commitment share warrants and other warrants, all subject to contractual ownership limitations that generally cap actual holdings at about 4.9–4.99% unless increased upon notice.
Glucotrack, Inc. (GCTK) implemented a 1-for-15 reverse stock split of its common stock, effective at 4:30 p.m. Eastern Time on August 28, 2026, pursuant to a Certificate of Amendment filed with the Delaware Secretary of State and previously approved by stockholders on August 18, 2026.
Every 15 issued and outstanding shares of common stock were automatically combined into one share, with no change to the par value or to the authorized 250,000,000 common shares. Outstanding shares were reduced from 11,972,157 to approximately 798,144, and related stock options and warrants and their exercise prices were adjusted proportionally. No fractional shares were issued; holdings were rounded up to the next whole share. The common stock will begin trading on a split-adjusted basis on August 31, 2026 under ticker GCTK with new CUSIP 45824Q887.
Glucotrack, Inc. (GCTK) filed an amendment to a prior current report to add required financial information related to a previously completed reverse merger with Lokahi Therapeutics Inc. The amendment supplies historical financial statements, pro forma consolidated financial information, and a detailed management discussion and analysis for Lokahi.
The amendment attaches unaudited condensed financials for the six months ended June 30, 2026 and 2025, audited financial statements for the years ended December 31, 2025 and 2024, MD&A for Lokahi, and unaudited pro forma consolidated information. It does not report new events beyond what was described in the earlier acquisition completion report.
Glucotrack, Inc. (GCTK) filed an amended current report to add historical and pro forma financial information for Lokahi Therapeutics, Inc. related to a previously completed reverse merger in which Lokahi’s shareholders received 90.0% of the combined company’s fully diluted equity.
Lokahi is a development-stage biopharmaceutical company developing Apitox/LT‑100 for knee osteoarthritis and has no revenue. For the six months ended June 30, 2026, it recorded a net loss of $8.1 million (vs. $3.1 million in 2025) and had cash of $53,186, total assets of $2.5 million, and total liabilities of $9.2 million, resulting in a shareholders’ deficit of $6.7 million. Auditors and management highlight recurring losses, negative operating cash flows and limited cash as raising substantial doubt about Lokahi’s ability to continue as a going concern.
Lokahi’s capital structure includes $5.0 million of secured promissory notes to a trust with $6.1 million due in aggregate and significant near‑term maturities, driving $2.2 million of interest expense in the first half of 2026. Under a settlement with its former parent APUS, Lokahi contributed up to $3.0 million of working capital, assumed related‑party notes, and received a CRO credit facility of about $2.2 million plus full rights to the Apitox program. In the merger with GCTK, Lokahi holders received 1,311,200 GCTK common shares and 785,334 Series A convertible preferred shares, with GCTK’s pre‑merger stockholders retaining a 10.0% minimum fully diluted stake.
Glucotrack, Inc. (GCTK) announced that it will implement a 1-for-15 reverse stock split of its common stock, effective with the opening of trading on August 31, 2026. The stock will continue trading on the Nasdaq Capital Market under the symbol GCTK with a new CUSIP 45824Q887.
Stockholders had previously authorized management on August 18, 2026 to implement one or more reverse splits at ratios up to 1-for-30. The reverse split is intended to help Glucotrack regain compliance with Nasdaq’s $1.00 minimum bid price requirement. After the reverse split, the company must maintain a closing bid of at least $1.00 for each trading day through November 9, 2026 to remain listed, or its securities may be subject to delisting at Nasdaq’s discretion.
Glucotrack, Inc. (GCTK) reported the results of its 2026 annual stockholder meeting. There were 7,719,121 shares of common stock outstanding on the record date, and 2,786,974 votes (about 36.10%) were represented in person or by proxy, constituting a quorum.
Stockholders elected six directors to serve until the 2027 annual meeting. They also approved, on an advisory basis, the 2025 executive compensation, and ratified CBIZ CPAs P.C. as independent registered public accounting firm for the year ending December 31, 2026.
Stockholders approved amendments to permit one or more reverse stock splits at an aggregate ratio of up to 1-for-30, and approved a warrant inducement involving repricing certain existing warrants, issuing new inducement warrants and issuing common shares upon their exercise, for purposes of complying with Nasdaq Listing Rule 5635(d).
Glucotrack, Inc. reported a net loss of $8,148k for the six months ended June 30, 2026, an improvement from a $11,589k loss a year earlier, as research and development expenses fell to $4,148k from $5,021k. General and administrative expenses were $3,455k versus $3,273k.
Total assets declined to $1,495k, with cash and cash equivalents dropping to $1,124k from $7,383k, while total liabilities were $3,236k, resulting in a stockholders’ deficit of $1,741k. Operating cash outflow was $7,664k in the first half of 2026.
The company raised equity through its 6B ELOC and warrant exercises, increasing common shares outstanding to 6,259,279 at June 30, 2026 and subsequently completed a Business Combination with Lokahi Therapeutics on July 14, 2026. Management disclosed substantial doubt about the ability to continue as a going concern and highlighted Nasdaq listing deficiencies related to minimum bid price and stockholders’ equity, as well as new Bridge Financing and a $50,000 ELOC facility to support liquidity.
Glucotrack, Inc. is calling a virtual special stockholders’ meeting on September 11, 2026 to approve three proposals related to significant equity issuances and meeting adjournment mechanics.
Proposal 1 seeks approval under Nasdaq Listing Rule 5635(d) for the full issuance of common stock to White Lion Capital, LLC under a three-year equity purchase facility (ELOC Purchase Agreement) of up to $50,000,000. This includes 2,505,513 commitment shares and shares underlying a commitment warrant of up to $10,000,000 in value, which together may exceed 20% of the 10,578,822 shares outstanding as of July 14, 2026. Failure to obtain approval within 60 days would trigger $50,000 liquidated damages per 30-day period.
Proposal 2 seeks approval for the full issuance of shares issuable upon conversion of senior secured convertible Bridge Notes and exercise of Bridge Warrants issued for approximately $7.95 million of gross proceeds. At the current Floor Price of $0.079824, full conversion of outstanding principal would yield about 89,096,154 shares, and full warrant exercise could add about 159,605,930 shares, both well above the 20% Nasdaq threshold. Proposal 3 would allow adjournment of the meeting to solicit additional proxies if needed.
Glucotrack, Inc. amended its July 14, 2026 Common Stock Purchase Agreement with White Lion Capital, LLC. The amendment sets a commitment fee of $1,000,000, to be paid in 2,505,513 shares of common stock issued within one business day after the related resale registration statement becomes effective. A new true-up mechanism requires Glucotrack to pay a cash True-Up Amount if the Commitment Fee Price is below the Minimum Price, equal to $1,000,000 minus 2,505,513 multiplied by the Commitment Fee Price, within 120 days after the Measurement Date. No true-up is owed if the Commitment Fee Price equals or exceeds the Minimum Price. All other terms of the equity line of credit agreement remain in effect, and the commitment share issuance relies on private offering exemptions under Section 4(a)(2) and Rule 506(b) of Regulation D.
Glucotrack, Inc. arranged approximately $5.5 million of new capital with institutional investors, consisting of a $3.5 million follow-on senior secured convertible note financing and a $2.0 million equity-linked private placement. The company stated the $0.75-per-unit equity financing was priced at a premium to market.
The Follow-On Bridge Notes have an aggregate face amount of $4,487,179 (22% original issue discount), bear 8% annual interest, mature nine months from July 14, 2026, carry an 18% default rate, and are secured by a first-priority lien on most company assets. After stockholder approval under Nasdaq Listing Rule 5635(d), they become convertible at the lower of the Nasdaq Minimum Price or 80% of the lowest daily VWAP over 15 trading days, subject to a 20% floor. Follow-On Bridge Warrants become exercisable for five years after approval, with a formula-based exercise price and similar floor protections. In the Interim PIPE, Glucotrack issued 2,666,667 pre-funded warrants and 2,666,667 common warrants (exercise price $1.50) for $2,000,000 in gross proceeds, with a 4.99% (or 9.99%) beneficial ownership cap and resale registration rights under a Registration Rights Agreement.